

Technical Data Sheet

PE-Cy™7 Rat Anti-Mouse CD25**Product Information**


Material Number:	552880
Alternate Name:	IL-2 Receptor α chain, p55
Size:	0.1 mg
Concentration:	0.2 mg/ml
Clone:	PC61
Immunogen:	IL-2-dependent cytolytic mouse T-cell clone B6.1
Isotype:	Rat (OFA) IgG1, λ
Reactivity:	QC Testing: Mouse
Storage Buffer:	Aqueous buffered solution containing $\leq 0.09\%$ sodium azide.

Description

The PC61 antibody reacts with CD25, the low-affinity IL-2 Receptor α chain (IL-2R α , p55) expressed on activated T and B lymphocytes from all mouse strains tested. IL-2R α by itself is not a signaling receptor. However, it can combine with IL-2 Receptor β (CD122) and γ c (CD132) chains to form high-affinity, signaling receptor complexes for IL-2. Resting T and B lymphocytes and resting and activated NK cells do not express IL-2R α . CD25 is transiently expressed at a low level during normal B-cell development in the bone marrow on the CD45R/B220low TdT- sIg- Pre-B/Pre-B-II and CD45R/B220low TdT- sIgM+ sIgD- immature B stages, but not on the CD45R/B220low TdT+ sIg- Pro-B/Pre-B-I stage nor on CD45R/B220high TdT- sIgM+ sIgD+ mature B cells. It is expressed at a higher level during a very early stage of T-cell development in fetal and adult thymus. Peripheral CD25+CD4+ lymphocytes called regulatory T (Treg) cells are involved in the maintenance of self-tolerance. It has also been reported that dendritic cells express CD25, recognized by mAb 7D4 (Cat. No. 553068). The PC61 antibody recognizes an epitope of CD25 which is distinct from the IL-2 binding site and from those recognized by mAbs 3C7 (Cat. No. 557364) and 7D4 (Cat. No. 553068). It blocks binding of IL-2 to CD25, presumably by inducing a conformational change in CD25.

Use of this product can fall under one or more claims of the following patents licensed to Becton, Dickinson and Company: US Patent Nos. 5,445,939, 5,656,446, 5,843,689; European Patent No. 319,543; Canadian Patent No. 1,296,622; Australian Patent No. 615,880; and Japanese Patent No. 2,769,156.

This antibody is routinely tested by flow cytometric analysis. Other applications were tested at BD Biosciences Pharmingen during antibody development only or reported in the literature.



Two-color analysis of the expression of CD25 in bone marrow. BALB/c bone marrow leukocytes were stained with FITC-conjugated anti-mouse CD45R/B220 mAb RA3-6B2 (Cat. No. 553087/553088) and either PE-Cy7-conjugated rat IgG1, λ isotype control mAb A110-1 (Cat. No. 552869, left panel) or PE-Cy7-conjugated PC61 antibody (right panel). Please note that the dead leukocytes were not excluded in this experiment, and the typical diagonal dead-cell population appears in the left panel. The same dead-cell population is partially obscured in the right panel. Flow cytometry was performed on a BD FACSCalibur™ flow cytometry system.

BD Biosciences

bdbiosciences.com

United States	Canada	Europe	Japan	Asia Pacific	Latin America/Caribbean
877.232.8995	888.259.0187	32.53.720.550	0120.8555.90	65.6861.0633	55.11.5185.9995

For country-specific contact information, visit bdbiosciences.com/how_to_order/

Conditions: The information disclosed herein is not to be construed as a recommendation to use the above product in violation of any patents. BD Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Purchase does not include or carry any right to resell or transfer this product either as a stand-alone product or as a component of another product. Any use of this product other than the permitted use without the express written authorization of Becton Dickinson and Company is strictly prohibited.

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Not for resale.

BD, BD Logo and all other trademarks are the property of Becton, Dickinson and Company. ©2006 BD

**BD Biosciences**

Preparation and Storage

The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.

The antibody was conjugated with PE-Cy7 under optimum conditions, and unconjugated antibody and free PE-Cy7 were removed by gel filtration chromatography.

Store undiluted at 4° C and protected from prolonged exposure to light. Do not freeze.

Application Notes

Application

Flow cytometry	Routinely Tested
----------------	------------------

Suggested Companion Products

Catalog Number	Name	Size	Clone
552869	PE-Cy7 Rat IgG1, λ Isotype Control	0.1 mg	A110-1
553087	FITC Rat Anti-Mouse CD45R/B220	0.1 mg	RA3-6B2

Product Notices

1. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
2. Please refer to www.bdbiosciences.com/pharmingen/protocols for technical protocols.
3. For fluorochrome spectra and suitable instrument settings, please refer to our Fluorochrome Web Page at www.bdbiosciences.com/pharmingen/colors.
4. PE-Cy7 is a tandem fluorochrome composed of R-phycoerythrin (PE), which is excited by the 488-nm line of a laser and serves as an energy donor, coupled to the cyanine dye Cy7™, which acts as an energy acceptor and fluoresces at 780 nm. BD Biosciences Pharmingen has maximized the fluorochrome energy transfer in PE-Cy7, thus maximizing its fluorescence emission intensity and minimizing residual emission from PE. Note: Although every effort is made to minimize the lot-to-lot variation in residual emission from PE, it is strongly recommended that every lot be tested for differences in the amount of compensation required and that individual compensation controls are run for each PE-Cy7 conjugate.
5. PE-Cy7 tandem fluorochrome emission is collected in a detector for fluorescence wavelengths of 750 nm and higher. PE-Cy7-labeled antibodies can be used with FITC- and R-PE-labeled reagents in single-laser flow cytometers with no significant spectral overlap between PE-Cy7 and FITC.
6. PE-Cy7 is optimized for use with a single argon ion laser emitting 488-nm light. Because of the broad absorption spectrum of the PE-Cy7 tandem fluorochrome, extra care must be taken when using dual-laser cytometers which may directly excite both PE and Cy7™. We recommend the use of cross-beam compensation during data acquisition or software compensation during data analysis.
7. Please observe the following precautions: Absorption of visible light can significantly alter the energy transfer occurring in any tandem fluorochrome conjugate; therefore, we recommend that special precautions be taken (such as wrapping vials, tubes, or racks in aluminum foil) to prevent exposure of conjugated reagents, including cells stained with those reagents, to room illumination.
8. Warning: Some APC-Cy7 and PE-Cy7 conjugates show changes in their emission spectrum with prolonged exposure to formaldehyde. If you are unable to analyze fixed samples within four hours, we recommend that you use BD™ Stabilizing Fixative (Cat. No. 338036).
9. Cy™ is a trademark of Amersham Biosciences Limited.
10. This product is subject to proprietary rights of Amersham Biosciences Corp. and Carnegie Mellon University and made and sold under license from Amersham Biosciences Corp. This product is licensed for sale only for research. It is not licensed for any other use. If you require a commercial license to use this product and do not have one return this material, unopened to BD Biosciences, 10975 Torreyana Rd, San Diego, CA 92121 and any money paid for the material will be refunded.
11. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.

References

- Ceredig R, Lowenthal JW, Nabholz M, MacDonald HR. Expression of interleukin-2 receptors as a differentiation marker on intrathymic stem cells. *Nature*. 1985; 314(6006):98-100.(Clone-specific: Blocking, Immunohistochemistry)
- Chen J, Ma A, Young F, Alt FW. IL-2 receptor alpha chain expression during early B lymphocyte differentiation. *Int Immunol*. 1994; 6(8):1265-1268.(Biology)
- Garni-Wagner BA, Witte PL, Tutt MM, et al. Natural killer cells in the thymus. Studies in mice with severe combined immune deficiency. *J Immunol*. 1990; 144(3):796-803.(Biology)
- Godfrey DI, Zlotnik A. Control points in early T-cell development. *Immunol Today*. 1993; 14(11):547-553.(Biology)
- Lowenthal JW, Cortes P, Toungue C, Lees R, MacDonald HR, Nabholz M. High and low affinity IL 2 receptors: analysis by IL 2 dissociation rate and reactivity with monoclonal anti-receptor antibody PC61. *J Immunol*. 1985; 135(6):3988-3994.(Immunogen: Blocking, Flow cytometry)
- Lowenthal JW, Zubler RH, Nabholz M, MacDonald HR. Similarities between interleukin-2 receptor number and affinity on activated B and T lymphocytes. *Nature*. 1985; 315(6021):669-672.(Clone-specific: Blocking, Immunoprecipitation)
- Moreau JL, Nabholz M, Diamantstein T, Malek T, Shevach E, Theze J. Monoclonal antibodies identify three epitope clusters on the mouse p55 subunit of the interleukin 2 receptor: relationship to the interleukin 2-binding site. *Eur J Immunol*. 1987; 17(7):929-935.(Clone-specific: Blocking)
- Read S, Malmstrom V, Powrie F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. *J Exp Med*. 2000; 192(2):295-302.(Biology)